Clinical Trial Update: Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). [Phase 3]

View source ↗

Summary

Phase 3 POD1UM-303/InterAACT 2 trial evaluating adding retifanlimab to carboplatin-paclitaxel versus placebo in locally advanced or metastatic anal canal squamo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Anal Canal

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Retifanlimab (retifanlimab)

Snippet

Sponsor: Incyte Corporation | Conditions: Squamous Cell Carcinoma of the Anal Canal | Phase 3 | Status: COMPLETED | Results posted: 2025-05-23